• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
181764 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

; b2 ^) I& i9 a" E3 v3 Q6 b8 F& ?5 H7 M可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  & H/ ?) M# O( b
- m$ V  h+ M  v+ v& K
$ o' M$ Y) s% b- S  K* c$ a
Sub-category:$ T! A. ?6 {8 `8 e0 ^
Molecular Targets
! b% ]' u" m; N1 }" w* G9 Y
/ x1 W( L( P/ H- |
' g0 \8 p4 C: d" |Category:+ \1 h' d5 t/ y) Y" E
Tumor Biology
- L, n' e4 b7 j4 j. K9 g# p
8 n0 V6 A, O4 @8 R, ^# O# _9 y
5 l4 n" ^! X& j& a' PMeeting:2 {$ A5 _& g- O& p9 J
2011 ASCO Annual Meeting 3 j/ ~; n2 ]% c# k, d+ I/ U' `; N

, }5 N+ }' |( E& T0 G. \, W$ r
- u/ _' w5 V" e; zSession Type and Session Title:9 B5 X/ O& \0 X
Poster Discussion Session, Tumor Biology % k: ~9 J  C( n" T' b) c6 }0 ^6 G2 L
2 j9 S( C3 b$ z" J) {7 E7 v

* P# ~9 U# w/ Q, o9 ]Abstract No:
! k3 \/ E5 l" L. v- K10517
$ l$ ]: Z+ ?9 {7 M9 W
9 z/ O4 }9 `% B: P) m9 I7 S- ~7 C6 j  Q* ]
Citation:
* B: r3 o# u, R: w6 I  yJ Clin Oncol 29: 2011 (suppl; abstr 10517)
/ q* x% y% P0 ^; F% A  b0 G: l
. J, h, W% q) L( ~- x- j- d3 G5 A- C/ o1 M9 P1 k9 H
Author(s):( \! a. @2 S  V; C5 A$ X' N2 h
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
' ~% b5 p0 l5 X6 D7 O% G( b: f
; \5 f+ A( D6 S& u- ?4 M9 Z8 [# `/ k3 I
; E- o) d2 H! R! x, L
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- l5 V' w1 \$ i. E0 s( u

( f9 \- |1 t" t0 q! QAbstract Disclosures
2 y5 K0 t) W7 f' J7 x5 |
! I2 n0 f$ [; F* ]2 RAbstract:
; C& d& H  n6 H0 d
8 r6 C3 r# x. |4 D, V9 s
. r/ j& @) u7 Y8 z0 S/ yBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." w/ O. ^. y( |8 k& _

% ~& O" u3 T9 ^ 7 e1 N. j4 }: f- p& b4 a
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37   j' b% c( d. @* T
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

* z  J7 |2 A* X2 \3 B0 a化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
# _2 q/ q( R5 `9 M# ^易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。: u+ H% U1 k( W0 E) g) N8 ^8 V
ALK一个指标医院要900多 ...

4 T5 A+ g" E; L& d& H平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 }2 J+ F4 o2 g+ `

/ Z3 X) I3 N8 R/ k) U现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表